T-VEC Immunotherapy Now Injected Into Liver Metastases – Medscape
Medscape |
T-VEC Immunotherapy Now Injected Into Liver Metastases
Medscape The oncologic immunotherapy talimogene laherparepvec (T-VEC, Amgen Inc), already approved for the treatment of melanoma in the United States, is now being explored for its potential to eradicate advanced tumors in patients with primary and metastatic … Targeted immunotherapy treatment shows promise for treating advanced stage liver tumors |
